Cell Signaling Technology

Erlin-2 Antibody

#2959 · western blot · $317

60
Evidence Score · Well-Established
Used by 91 independent labs across 100 papers. How we score this →
100
Citing papers
14k
Combined citations
Supplier page Find this product

Research areas

Cancer Immunotherapy and Biomarkers6Circular RNAs in diseases6Immune Cell Function and Interaction6MicroRNA in disease regulation6Adipose Tissue and Metabolism6Immunotherapy and Immune Responses5Cancer-related Molecular Pathways4Adipokines, Inflammation, and Metabolic Diseases4

Papers citing this product

1
Regulation of Heme Oxygenase-1 Expression through the Phosphatidylinositol 3-Kinase/Akt Pathway and the Nrf2 Transcription Factor in Response to the Antioxidant Phytochemical Carnosol
Journal of Biological Chemistry·2004·699 cit.·DOI
2
JAK mutations in high-risk childhood acute lymphoblastic leukemia
Proceedings of the National Academy of Sciences·2009·559 cit.·DOI
3
α-Synuclein Is Localized to Mitochondria-Associated ER Membranes
Journal of Neuroscience·2013·500 cit.·DOI
4
Staphylococcus aureus protein A induces airway epithelial inflammatory responses by activating TNFR1
Nature Medicine·2004·399 cit.·DOI
5
A multi-cellular 3D bioprinting approach for vascularized heart tissue engineering based on HUVECs and iPSC-derived cardiomyocytes
Scientific Reports·2018·370 cit.·DOI
6
Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group
Blood·2009·345 cit.·DOI
7
YAP-mediated mechanotransduction tunes the macrophage inflammatory response
Science Advances·2020·288 cit.·DOI
8
Role of estrogen receptor β in colonic epithelium
Proceedings of the National Academy of Sciences·2006·245 cit.·DOI
9
Estrogen Attenuates Ischemic Oxidative Damage via an Estrogen Receptor α-Mediated Inhibition of NADPH Oxidase Activation
Journal of Neuroscience·2009·241 cit.·DOI
10
The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice
The Journal of Pathology·2020·223 cit.·DOI

Rate this reagent

Used this in your lab? Leave a quick rating. Reviews are anonymous and verified by academic email before they appear.

Your email is never shown publicly.